Jákup Andreas Thomsen

Jákup Andreas Thomsen

Auto-generated profile, based on publicly available information

Jákup Andreas Thomsen

National Hospital

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2013 in Tropical Medicine & International Health
Verified
Journal Article
Closed access
PDF file
JRJon B. Rasmussen
Jon B. Rasmussen
JTJakúp A. Thomsen
Jakúp A. Thomsen
PRPeter Rossing
Peter Rossing
SPShelagh Parkinson
Shelagh Parkinson
DCDirk L. Christensen
Dirk L. Christensen
IBIb Christian Bygbjerg
Ib Christian Bygbjerg

1 January 2014
Verified
Book Chapter
Open access
PDF file
JTJákup Andreas Thomsen
Jákup Andreas Thomsen
ALAllan M Lund
Allan M Lund
JOJess Have Olesen
Jess Have Olesen
MMMagni Mohr
Magni Mohr
JRJan Rasmussen
Jan Rasmussen
Background: 3-Methylcrotonyl-CoA carboxylase deficiency (3-MCCd) is an autosomal recessive disorder in the catabolism of leucine. In the present study, we investigated the current and prior medical condition of patients with 3-MCCd in the Faroe Islands and their carnitine levels in blood, urine and muscle tissue with and without l-carnitine supplementation to evaluate the current treatment strategy of not recommending l-carnitine supplementation to Faroese 3-MCCd patients. Methods: Blood and urine samples and muscle biopsies were collected from patients at inclusion and at 3 months. Eight patients received l-carnitine supplementation when recruited; five did not. Included patients who received supplementation were asked to stop l-carnitine, the others were asked to initiate l-carnitine supplementation during the study. Symptoms were determined by review of hospital medical records and questionnaires answered at baseline and after the intervention. Results: The prevalence of 3-MCCd in the Faroe Islands was 1:2,400, the highest reported worldwide. All patients were homozygous for the MCCC1 mutation c.1526delG. When not administered l-carnitine, the 3-MCCd patients (n = 13) had low plasma and muscle free carnitine levels, 6.9 (SD 1.4) μmol/L and 785 (SD 301) nmol/g wet weight, respectively. l-Carnitine supplementation increased muscle and plasma carnitine levels to a low-normal range, 25.5 (SD 10.9) μmol/L and 1,827 (SD 523) nmol/g wet weight, p < 0.01, respectively. Seven of the thirteen 3-MCCd subjects suffered from self-reported fatigue with some alleviation after l-carnitine supplementation. Conclusion: 3-MCCd is common in the Faroe Islands. Some symptomatic 3-MCCd patients may benefit biochemically and clinically from l-carnitine supplementation, a more general recommendation cannot be given.